# Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension

> **NCT02031861** · PHASE4 · COMPLETED · sponsor: **Shanghai Shyndec Pharmaceutical Co., Ltd.** · enrollment: 38 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** nifedipine CR tablets (Xin Ran)
- **DRUG:** nifedipine CR tablets (Adalat)

## Key facts

- **NCT ID:** NCT02031861
- **Lead sponsor:** Shanghai Shyndec Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02031861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02031861, "Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02031861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*